LivaNova PLC (LIVN)

83.24 -0.26 (-0.31%) At close: 4:00PM EDT

LivaNova PLC

20 Eastbourne Terrace
Paddington
London W2 6LG
United Kingdom
44 20 3325 0660
http://www.livanova.com

Sector(s): Healthcare
Industry: Medical Devices
Full Time Employees: 4,000

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Damien McDonald	CEO & Director	1.57M	N/A	1965
Ms. Keyna Pidcock Skeffington	Sr. VP, Gen. Counsel & Corp. Sec.	659.22k	N/A	1963
Mr. Alex Shvartsburg	Interim CFO and Corp. VP of Financial Planning, Analysis & International Region	N/A	N/A	N/A
Ms. Melissa Farina	VP of Investor Relations	N/A	N/A	N/A
Deanna Wilke	Director of Corp. Communications	N/A	N/A	N/A
Mr. Matthew Joseph Dodds III	Sr. VP of Corp. Devel.	N/A	N/A	N/A
Ms. Trui Hebbelinck	Chief HR Officer	N/A	N/A	1972
Mr. Pritpal Shinmar	Sr. VP of Global Market Access	N/A	N/A	1957
Dr. Bryan D. Olin	Sr. VP of Clinical, Quality Assurance & Regulatory Affairs	N/A	N/A	1967
Mr. Paul R. Buckman	Pres of North America & GM of Transcatheter Mitral Valve Replacement	N/A	N/A	1956

Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.

Corporate Governance

LivaNova PLC’s ISS Governance QualityScore as of April 30, 2021 is 4. The pillar scores are Audit: 5; Board: 3; Shareholder Rights: 4; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.